Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System
← catalyst calendarNCT04798261 · readout ≤ 134 d
Sponsored by Penumbra Inc. (industry) · PEN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
1,500estimated
Sites
79
Countries
Australia, Austria, Brazil +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-06-25 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2021-03-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pulmonary Embolism
Intervention
- Device: Indigo Aspiration System
Primary outcomes
what the primary-completion date above is the date OFSafety: Composite of major adverse events
measured 48 hours
Performance: Change in RV/LV Ratio
measured 48 hours post-procedure
Publications
- PMID 40878986 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PEN's whole pipeline · Catalyst calendar · Every registered study · What changed